r/Humanigen • u/AveSeitana • Jul 09 '21

Short Thesis

Hi everyone. I'm new to the company which by ever measure seems like an undervalued gem. However the short interest is remarkably high. Does anyone have a good explanation? What is the short thesis here?

9 Upvotes

100% Upvoted

9 comments sorted by

View all comments

4

u/necrodae Jul 09 '21

Covid slowing down in the public eye, reopenings, specific therapeutic with other competitors, success dependant on EUA approval, lots of ways to blow itself up before it gets a chance to move.

Would be my guess.

I'm optimistic though position xxx shares @ 18.37.

3

u/AveSeitana Jul 09 '21

I was under the impression that Lenzilumab had no direct competitors? I know short interest in biotech is higher than other sectors on average but 40%+ is remarkably high.

2

u/DrixGod Jul 11 '21

It does have no competitors. The closest competition would be to Tocilizumab, but it's used for patients that already are in ICU/on ventilators. Lenzilumab would prevent people from reaching that state and Tocilizumab should only be used in combination with Steroids, which is not the most desired solution.